Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND Diabetes and non-diabetic dysglycaemia are risk factors for accelerated cognitive decline. In this planned substudy of the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, we assessed whether normalising glucose with insulin glargine or administering omega-3 fatty acids in this population may slow this process or affect the development of cognitive impairment. METHODS The ORIGIN trial recruited participants older than 50 years with dysglycaemia who were taking either no or one oral glucose-lowering drug, who had additional risk factors for cardiovascular events, whose HbA1c was less than 9%, and who were not taking insulin. Participants were recruited from 573 sites in 40 countries. Participants were randomly assigned to either titrated basal insulin glargine targeting a fasting plasma glucose concentration of 5.3 mmol/L or lower or standard care and to either omega-3 fatty acid (1 g) or placebo by a factorial design. Outcome adjudicators and data analysts were masked to treatment allocation. Cognitive function was assessed by the Mini-Mental State Examination (MMS) and Digit Symbol Substitution (DSS). The effect of insulin glargine or omega-3 fatty * acid on cognitive function over time, the annualised change in test scores, and the development of probable cognitive impairment were measured. All analyses were restricted to those participants who had a cognitive measurement at both baseline and at least one follow-up visit. The ORIGIN trial is registered with ClinicalTrials.gov, NCT00069784. FINDINGS Participants were randomly assigned between Sept 1, 2003, and Dec 15, 2005. MMSE and DSS were assessed in 11,685 and 3392 ORIGIN participants (mean age 63.4 years [SD 7.7]), who were followed up for a median of 6.2 years (IQR 5.8-6.7). There was no difference in the rate of change of cognitive test scores between the insulin glargine and standard care groups (for the MMSE 0.0046, 95% CI -0.0132 to 0.0224, p=0.39; and for the DSS -0.0362, -0.2180 to 0.1455, p=0.34) or between the omega-3 fatty acid and placebo groups (for the MMSE 0.0013, 95% CI -0.0165 to 0.0191, p=0.21; and for the DSS -0.0605, -0.2422 to 0.1212, p=0.72). Similarly, the incidence of probable cognitive impairment did not differ between the insulin glargine and standard care groups (p=0.065) or the omega-3 fatty acid and placebo groups (p=0.070). In a subgroup analysis, allocation to insulin glargine versus standard care seemed to reduce the decline in the MMSE (but not the DSS) in participants with dysglycaemia but without evidence of diabetes (pinteraction=0.024). INTERPRETATION In this relatively young cohort of people with dysglycaemia, insulin mediated normoglycaemia and omega-3 fatty acid for over 6 years had a neutral effect on the rate of cognitive decline and on incident cognitive impairment. Future studies should assess the effect of these interventions in an older cohort or the effect of other glucometabolic interventions on cognitive decline. FUNDING Sanofi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mini‐Mental State Examination: A Comprehensive Review
Tombaugh, T. N., & McIntyre, N. J. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb01992.x · Cited by 5,152
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies
Cukierman, T., Gerstein, H. C., & Williamson, J. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0023-4 · Cited by 1,049
Self-citationCardiovascular risk factors and cognitive decline in middle-aged adults
Knopman, D., Boland, L. L., Mosley, T., Howard, G., Liao, D., Szklo, M., McGovern, P., & Folsom, A. R. (2001) · Neurology · doi:10.1212/wnl.56.1.42 · Cited by 883
Adherence to a Mediterranean Diet, Cognitive Decline, and Risk of Dementia
Féart, C. (2009) · JAMA · doi:10.1001/jama.2009.1146 · Cited by 757
Long-term effect of diabetes and its treatment on cognitive function
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa066397 · Cited by 646
Relation of diabetes to mild cognitive impairment
Luchsinger, J. A., Reitz, C., Patel, B., Tang, M.-X., Manly, J. J., & Mayeux, R. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.570 · Cited by 592
Is Diabetes Associated With Cognitive Impairment and Cognitive Decline Among Older Women?
Gregg, E. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.2.174 · Cited by 521
Ageing and diabetes: implications for brain function
Biessels, G. J., van der Heide, L. P., Kamal, A., Bleys, R. L. A. W., & Gispen, W. H. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01486-3 · Cited by 458
Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease
Watson, G. S., & Craft, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.048 · Cited by 307
Cited by
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Type 2 diabetes and cognitive dysfunction–towards effective management of both comorbidities
Srikanth, V., Sinclair, A. J., Hill-Briggs, F., Moran, C., & Biessels, G. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30118-2 · Cited by 465
Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review
Geijselaers, S. L. C., Sep, S. J. S., Stehouwer, C. D. A., & Biessels, G. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70148-2 · Cited by 377
Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300
Self-citationAreosa Sastre, A., Vernooij, R. W., González-Colaço Harmand, M., & Martínez, G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003804.pub2 · Cited by 272
Metadata
- Authors
- Cukierman-Yaffe, T., Bosch, J., Diaz, R., Dyal, L., Hancu, N., Hildebrandt, P., Lanas, F., Lewis, B. S., Marre, M., Yale, J.-F., Yusuf, S., & Gerstein, H. C.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 2
- Issue
- 7
- Pages
- 562-572
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2133596089
- Cited by
- 64
- References
- 17
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. https://app.cochat.ai/papers/10.1016/s2213-8587(14)70062-2
- The paper
- Cukierman-Yaffe, T., Bosch, J., Diaz, R., Dyal, L., Hancu, N., Hildebrandt, P., Lanas, F., Lewis, B. S., Marre, M., Yale, J.-F., Yusuf, S., & Gerstein, H. C. (2014). Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(14)70062-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.